FilingSEC EDGAR6-K
BioLineRx Confirms Presentation of GLIX1 Preclinical Data and Clinical Design at EANO 2026
· SEC accepted
StagePhase 1/2a
Filing content
BioLineRx will present preclinical efficacy data and the Phase 1/2a clinical trial design for GLIX1 at the upcoming European Association of Neuro-Oncology meeting.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…